Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
KIF15 confers resistance to enzalutamide in castration resistant prostate cancer [array]
PubMed Similar studies Analyze with GEO2R
KIF15 promotes AR and AR-V7 protein stabilization in contribution to enzalutamide resistance of prostate cancers
KIF15 confers resistance to enzalutamide in castration resistant prostate cancer [RNA-Seq]
PubMed Similar studies Analyze with GEO2RSRA Run Selector
Transcriptome analysis of Enzalutamide-resistant C4-2B (C4-2B MDVR) cells treated with Indocin.
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
RNA-Seq analysis of prostate tumors with or without androgen receptor splice variant
Profiles of prostate cancer cell lines
PubMed Full text in PMC Similar studies
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Role of androgen receptor splice variant 7 (AR-v7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
PubMed Full text in PMC Similar studies Analyze with GEO2R
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (Affymetrix)
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq)
Targeting DNMTs to overcome enzalutamide resistance in prostate cancer
RNA-seq control (sgNT) and TLE3KO (sgTLE3) cells treated with 10 uM enzalutamide or vehicle
Endogenous Androgen Receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis
PubMed Full text in PMC Similar studies SRA Run Selector
Differential gene expression induced by Enzalutamide in a prostate cancer xenograft
J_093015-circRNA-33 AS-CR-005 Human CircRNA V2 microarray 01272016
Expression data from C42B prostate cancer cell line treated with enzalutamide and/or sphingosine kinase inhibitor PF-543 or ABC294640
Expression data from LNCaP cells treated with DHT and enzalutamide
Expression data from prostate cancer LNCaP-AdtHs cells in response to androgen, ADT, normoxia, or hypoxia
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on